Agenus (NASDAQ:AGEN) : Traders are bullish on Agenus (NASDAQ:AGEN) as it has outperformed the S&P 500 by a wide margin of 17.85% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.34%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.78% in the last 1 week, and is up 19.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -48.05% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $9.64 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $4.12 and the 200 Day Moving Average price is recorded at $3.78.
The stock has recorded a 20-day Moving Average of 17.16% and the 50-Day Moving Average is 23.41%.
Agenus (NASDAQ:AGEN): stock turned positive on Friday. Though the stock opened at $4.68, the bulls momentum made the stock top out at $4.87 level for the day. The stock recorded a low of $4.56 and closed the trading day at $4.79, in the green by 2.13%. The total traded volume for the day was 1,630,781. The stock had closed at $4.69 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Agenus Inc, Armen Garo H had purchased shares worth of $318,000 in a transaction dated on May 6, 2016. A total of 100,000 shares were purchased at a price of $3.18 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).